Obtenga las últimas noticias sobre las acciones de Kazia Therapeutics con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de KZIA

Últimas noticias sobre

KAZIA THERAPEUTICS-SPON ADR

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

Press Releases

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)

News

Small-Cap Disruptors KZIA, SNYR, HSDT, TRNR, PRSO Lead Momentum – More Microcap Stocks Inside

Small Cap

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

Opinion

Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up

Contracts

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program

Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

AMZN

CLDI

COST

HSDT

IMNN

IMRX

INEO

KBSX

KZIA

NUVB

ONCY

PNPNF

PRSO

SNYR

TRNR

TSX:ONC

TSXV:PNPN

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

Ernexa Therapeutics

Evogene

FibroBiologics

Imunon

Immuron Limited - American Depositary Shares

Immuron

Mustang Bio

Marker Therapeutics

OSR Holdings

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Propanc Biopharma

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Maxim Group

HC Wainwright & Co.

Comments

Kazia Therapeutics Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL